| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
866,609 |
| 52
Week Range: |
$191.51 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
55,541 |
496,602 |
| Total Sell Value |
$0 |
$0 |
$11,412,520 |
$89,768,813 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
19 |
72 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Akkaraju Srinivas |
Director |
– • – |
2020-05-05 |
4 |
OE |
$20.06 |
$170,510 |
D/D |
8,500 |
48,668 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2020-05-05 |
4 |
S |
$166.11 |
$840,226 |
D/D |
(5,056) |
52,575 |
|
-12% |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-05-05 |
4 |
S |
$164.80 |
$4,085,341 |
D/D |
(24,598) |
743,741 |
|
-12% |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2020-05-05 |
4 |
OE |
$15.46 |
$865,277 |
D/D |
39,059 |
173,888 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2020-05-05 |
4 |
S |
$162.45 |
$4,377,596 |
D/D |
(26,867) |
161,696 |
|
-12% |
|
| Lippman Marc E |
Director |
– • – |
2020-05-04 |
4 |
S |
$152.03 |
$152,030 |
D/D |
(1,000) |
130,313 |
|
-10% |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2020-05-04 |
4 |
S |
$147.00 |
$2,082,556 |
D/D |
(14,167) |
161,696 |
|
-10% |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2020-05-04 |
4 |
OE |
$12.00 |
$170,004 |
D/D |
14,167 |
175,863 |
|
- |
|
| Baker Julian |
Director |
– • • |
2020-04-23 |
4 |
OE |
$12.76 |
$446,600 |
I/I |
35,000 |
45,860,149 |
|
- |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2020-04-21 |
4 |
D |
$139.92 |
$162,164 |
D/D |
(1,159) |
117,233 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2020-04-21 |
4 |
D |
$139.92 |
$128,724 |
D/D |
(920) |
191,582 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2020-04-21 |
4 |
D |
$139.92 |
$79,752 |
D/D |
(570) |
161,696 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-04-21 |
4 |
D |
$139.92 |
$422,969 |
D/D |
(3,023) |
768,339 |
|
- |
|
| Liu Jean I |
GC/EVP, Leg Afairs |
• – – |
2020-04-19 |
4 |
D |
$139.92 |
$90,246 |
D/D |
(645) |
73,474 |
|
- |
|
| Liu Jean I |
GC/EVP, Leg Afairs |
• – – |
2020-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
2,734 |
74,119 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2020-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
2,186 |
57,631 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2020-04-19 |
4 |
D |
$139.91 |
$45,612 |
D/D |
(326) |
56,809 |
|
- |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2020-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
10,733 |
118,392 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2020-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
3,828 |
192,502 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2020-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
3,828 |
162,266 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
12,578 |
771,362 |
|
- |
|
| Romp Charles R |
EVP, CommercialOfficer |
• – – |
2020-04-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
55,771 |
|
24% |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-04-08 |
4 |
AS |
$119.25 |
$3,416,814 |
D/D |
(28,472) |
758,784 |
|
32% |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-04-08 |
4 |
OE |
$12.00 |
$341,664 |
D/D |
28,472 |
779,866 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-03-09 |
4 |
AS |
$105.29 |
$3,134,578 |
D/D |
(28,472) |
758,784 |
|
54% |
|
1805 Records found
|
|
Page 17 of 73 |
|
|
